-

Aptorum Group Interview to Air on Bloomberg International on the RedChip Money Report

NEW YORK--(BUSINESS WIRE)--Regulatory News:

Aptorum Group Limited (NASDAQ: APM), a biopharmaceutical company focused on the development of novel therapeutics to address global unmet medical needs, today announced an interview with its President, Daniel Lui, will air on The RedChip Money Report television program. The interview will air Sunday, August 30, at 6 p.m. local time on Bloomberg International, available in 100+ million homes across Europe.

In the exclusive interview, Lui provides an overview of the Company’s development pipeline and near-term commercialization efforts.

To view the interview segment, please visit: https://youtu.be/rjvqZfs5zqk

The interview will also air in the US on the Action Channel on Sunday August 30 at 11 a.m. ET and is available via live stream on American Business TV.

“The RedChip Money Report" delivers insightful commentary on small-cap investing, interviews with Wall Street analysts, financial book reviews, as well as featured interviews with executives of public companies.

About Aptorum Group

Aptorum Group Limited (Nasdaq: APM) is a pharmaceutical company dedicated to developing and commercializing novel therapeutics to tackle unmet medical needs. Aptorum Group’s current drug pipeline includes indications in orphan diseases, infectious diseases and metabolic diseases and a number of which are targeted to enter clinical trial phases in 2020. Aptorum Group also operates a women’s health supplement business whose Dioscorea opposita Bioactive Nutraceutical Tablets are currently being commercialized.

For more information about the Company, please visit www.aptorumgroup.com.

Contacts

U.S. Investor Relations
RedChip Companies, Inc.
Dave Gentry
407-491-4498

Media
info@aptorumgroup.com
+44 020 80929299

Industry:

Aptorum Group Limited

NASDAQ:APM
Release Versions
EnglishFrench
Hashtags
#biopharmaceutical
#euronext
#nasdaq
#orphandrug

Contacts

U.S. Investor Relations
RedChip Companies, Inc.
Dave Gentry
407-491-4498

Media
info@aptorumgroup.com
+44 020 80929299

More News From Aptorum Group Limited

Aptorum Group Limited Reports Financial Results and Business Update for the Six Months Ended June 30, 2024

NEW YORK--(BUSINESS WIRE)--Aptorum Group Limited (NASDAQ: APM) (“Aptorum Group” or the “Company”), a clinical stage biopharmaceutical company dedicated to meeting unmet medical needs in oncology, autoimmune and infectious diseases, today provided a business update and announced financial results for the six months ended June 30, 2024. “Our team and Yoov have spent considerable time and effort on the due diligence process, the negotiation of definitive terms, and the preparation of necessary tra...

Aptorum Group Limited Reports 2023 Fiscal Year End Financial Results and Provides Business Update

NEW YORK & LONDON--(BUSINESS WIRE)--Aptorum Group Limited (Nasdaq: APM) (“Aptorum Group” or “We”), a clinical stage biopharmaceutical company dedicated to meeting unmet medical needs in oncology, autoimmune diseases and infectious diseases, today announced financial results for the fiscal year ended December 31, 2023, and provided an update on corporate developments. Mr. Ian Huen, Chief Executive Officer and Executive Director of Aptorum Group, commented, “Throughout 2023, we have maintained a...

Aptorum Group Ltd Announces Entering into an Agreement and Plan of Merger with YOOV Group Holding Ltd and a Split-off Agreement to Separate its Legacy Business

NEW YORK & LONDON--(BUSINESS WIRE)--Aptorum Group Limited (Nasdaq: APM), a clinical stage biopharmaceutical company (“Aptorum”), and privately-held YOOV Group Holding Ltd. (“YOOV”) jointly announced today that they entered into an Agreement and Plan of Merger (as it may be amended from time to time, the “Merger Agreement”). The Merger Agreement was approved by Aptorum’s and YOOV’s boards of directors (each board of directors, the “Board”), respectively. If the Merger Agreement is approved by Ap...
Back to Newsroom